Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma — Jean Yves Blay (2023) | RDL Network
Responses and prolonged PFS were observed in many tumours with BRAF mutations, including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas. Although not all cancer types responded, vemurafenib is an agnostic oncogene therapy of cancers.
Vivek Subbiah, Igor Puzanov, Jean Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric‐Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman
Vivek Subbiah, Igor Puzanov, Jean Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric‐Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman
Vivek Subbiah, Igor Puzanov, Jean Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric‐Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. De Jonge, Jean Yves Blay, Antoîne Italiano, Kan Yonemori, Daniel C. Cho, Filip YFL de Vos, Philippe Moreau, Elena Élez, Jan H.M. Schellens, Christoph Zielinski, Suman Redhu, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung‐Jue Bang
Discussion(0)
No comments yet. Be the first to comment.